APA (7th ed.) Citation

Harma Alma, Harma Alma, Corina de Jong, Corina de Jong, Janwillem Kocks, Janwillem Kocks, . . . Thys van der Molen. (2020). Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Harma Alma, Harma Alma, Corina de Jong, Corina de Jong, Janwillem Kocks, Janwillem Kocks, Janwillem Kocks, Thys van der Molen, and Thys van der Molen. Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M Et Al. in Frontiers in Pharmacology 2020; 10: 1519. Frontiers Media S.A., 2020.

MLA (9th ed.) Citation

Harma Alma, et al. Commentary: "Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease" by Dankers M Et Al. in Frontiers in Pharmacology 2020; 10: 1519. Frontiers Media S.A., 2020.